Welcome to our dedicated page for Nu-Med Plus SEC filings (Ticker: NUMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nu-Med Plus's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nu-Med Plus's regulatory disclosures and financial reporting.
Nu-Med Plus, Inc. (symbol: NUMD) is the issuer of record for a Form SCHEDULE 13D filing submitted to the SEC.
Nu-Med Plus, Inc. (symbol: NUMD) is the issuer of record for a Form 4 filing submitted to the SEC.
Nu-Med Plus, Inc. (NUMD) reported the initial insider holdings of Fred Tejada, who is a director, officer (SVP and Chief Geologist), and classified as a ten percent owner. The filing lists one holding entry for Common Stock with 0 shares owned directly following the reported date and no buy or sell transactions.
Nu-Med Plus, Inc. (NUMD) completed the acquisition, through its indirect wholly owned subsidiary Maritimes Gold Corp. (MGC), of a 100% beneficial interest in six gold mineral properties in Nova Scotia, New Brunswick, and Newfoundland and Labrador from MegumaGold Corp. and its subsidiaries. The properties include the Elmtree, Newfoundland, Killag, Goldenville, Miller Lake, and Caribou properties, together with associated assets.
As consideration, Nu-Med Plus issued 500,000 Series A Preferred shares to MegumaGold, granted a 5.0% net smelter returns royalty on each property to the Vendor or its subsidiaries, and MGC assumed post-transfer liabilities related to the properties and certain pre-existing royalties. Each Series A Preferred share votes and is convertible into 20 common shares, subject to beneficial ownership limitations (generally 4.999%, increaseable to 9.999% on notice). A contingent value protection feature may require Nu-Med Plus on the third anniversary measurement date to deliver additional common shares or cash if MegumaGold’s aggregate gross cash proceeds from qualifying sales of the preferred and resulting common shares are below $3.0 million, with any additional share issuance capped at 10% of Nu-Med Plus’ outstanding common stock as of that date.
Nu-Med Plus, Inc. reports June 30, 2026 quarterly results showing no revenue, total assets of $12,909 (including cash of $5,409) and liabilities of $280,395, resulting in a stockholders’ deficit of $267,486. The company recorded net income of $19,670 for the quarter and $3,792 for the six months, driven by $45,000 of other income from Avid Gold in exchange for transaction exclusivity.
Management states that current funds only support operations through August 31, 2026 and discloses planned expenditures of approximately $1,200,000 over the next 12 months, raising substantial doubt about the ability to continue as a going concern. Nu-Med Plus completed a share exchange to acquire 100% of Avid Gold via 4,500,000 shares of Series A Preferred Stock and agreed to acquire six Canadian gold properties for 500,000 additional Series A Preferred shares plus assumed liabilities, significantly pivoting toward gold exploration.
The company also highlights substantial related-party notes totaling $122,500, a $100,000 convertible note to be repaid by October 8, 2026, potential issuance of “True-Up” shares to the property vendor, and super-voting and preferred share structures that may lead to significant dilution and concentrated voting control. Disclosure controls and procedures are assessed as not effective.
Nu-Med Plus, Inc. completed the acquisition of Avid Gold Ltd, making Avid Gold and its subsidiary Maritimes Gold wholly owned in exchange for 4,500,000 shares of Series A Preferred Stock and the assumption of a $100,000 Avid Gold promissory note. Each Series A share is convertible into 20 common shares, subject to a beneficial ownership cap initially at 4.999% of outstanding common stock (electable up to 9.999%).
The company issued additional preferred equity: 225,000 Series A shares each to the Hayde Family Revocable Trust and CFO Keith Merrell, and 50,000 Series A shares to Hanover International as compensation, plus 1,000,000 Series X Super Voting Preferred shares to director and Sr. Vice President/Chief Geologist Fred Tejada. The Series X shares carry 100 votes per share.
Through the Series X issuance and a Voting Agreement with key insiders, Mr. Tejada controls voting power over 102,411,474 voting shares, or about 44.5% of the company’s approximately 230,220,035 voting shares, resulting in a change in control. The company plans to seek stockholder approval for a 1‑for‑27 reverse stock split, an increase in authorized common stock from 90,000,000 to 500,000,000, and a redomicile from Utah to Nevada. Registration rights were granted to register resales of common stock issuable from the preferred shares, and consulting agreements were entered with Mr. Hayde and Mr. Merrell. Separately, Nu‑Med and subsidiaries signed a Mineral Property Purchase Agreement to acquire six Canadian gold properties totaling over 30,900 acres, subject to closing conditions.